ACADIA Pharmaceuticals Inc.
ACADHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, ACADIA Pharmaceuticals Inc. focuses on Biotechnology services and products. ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The $4.83B market capitalization puts ACAD squarely in mid-cap range for its industry. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.
Market Cap
$4.83B
Beta
0.86
P/E (TTM)
12.56
P/E (Fwd)
31.48
EPS (TTM)
$2.23
EPS (Fwd)
$0.89
ROE
35.7%
ROA
3.6%
Cash
$956.5M
Total Debt
$73.9M
Free CF
$68.6M
52W Change
12.8%
Annual Financials
Cash vs Debt
Where ACAD stands vs its 150-day and 200-day moving averages
As of the August 31, 2026 close, ACAD finished 22.41% above its 150-day moving average ($23.78) and 19.55% above its 200-day moving average ($24.35). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ACAD overbought or oversold?
At the August 31, 2026 close, ACAD's RSI(14) was 48.2, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
ACADIA Pharmaceuticals Inc. holds $956.5M in cash against $73.9M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow comes in at $68.6M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 35.7% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 3.6% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $517.2M (2022) to $1.07B (2025), reflecting a 107% increase over the period.
With cash comfortably exceeding debt, ACAD has financial flexibility that may help navigate uncertain periods. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence ACADIA Pharmaceuticals Inc.'s trajectory.